A61K 39/0018
Combination vaccines based on acellular diphtheria-tetanus-pertussis
Official title: {Combination vaccines based on acellular diphtheria-tetanus-pertussis}
A61K39/0018 (Combination vaccines based on acellular diphtheria-tetanus-pertussis) appears on 63 US grants and 93 published applications in this corpus.
Search patents in A61K- Granted patents
- 63
- Published applications
- 93
- Assignees
- 39
- Inventors
- 138
- Latest grant
- 8 Apr 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 1 |
| 2002 | 1 | 1 |
| 2003 | 1 | 3 |
| 2004 | 1 | 3 |
| 2005 | 0 | 0 |
| 2006 | 0 | 2 |
| 2007 | 1 | 1 |
| 2008 | 0 | 4 |
| 2009 | 0 | 5 |
| 2010 | 0 | 9 |
| 2011 | 2 | 6 |
| 2012 | 2 | 2 |
| 2013 | 5 | 9 |
| 2014 | 8 | 5 |
| 2015 | 2 | 8 |
| 2016 | 6 | 4 |
| 2017 | 4 | 1 |
| 2018 | 7 | 6 |
| 2019 | 4 | 4 |
| 2020 | 3 | 4 |
| 2021 | 1 | 4 |
| 2022 | 2 | 2 |
| 2023 | 2 | 5 |
| 2024 | 5 | 3 |
| 2025 | 2 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Liquid six combined vaccine composition8 Apr 2025US 12,268,738 B2KM Biologics Co., Ltd.
- Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone or in combination using neurotoxin associated proteins25 Feb 2025US 12,233,119 B2Prime Bio, Inc.
- Immunogenic compositions comprising OMVs, an acellular pertussis antigen, a tetanus toxoid and a diphtheria toxoid29 Oct 2024US 12,128,094 B2Glaxosmithkline Biologicals SA
- Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same17 Sep 2024US 12,090,195 B2Serum Institute of India Private Limited
- Therapeutic compositions and methods with cytokine signaling immunomodulators27 Aug 2024US 12,070,492 B2Hennepin Healthcare Research Institute
- Immunogenic compositions13 Feb 2025US 2025/0049906 A1Glaxosmithkline Biologicals SA
- Composition for Oral or Nasal Delivery of Tetanus, Diphtheria, and Pertussis Vaccine alone or in combination using Neurotoxin Associated Proteins11 Jul 2024US 2024/0226262 A9Prime Bio, Inc.
- Liquid six combined vaccine composition20 Jun 2024US 2024/0197863 A1KM Biologics Co., Ltd.
- Composition for Oral or Nasal Delivery of Tetanus, Diphtheria, and Pertussis Vaccine alone or in combination using Neurotoxin Associated Proteins25 Apr 2024US 2024/0131137 A1Prime Bio, Inc.
- Dengue vaccine unit dose and administration thereof9 Nov 2023US 2023/0355748 A1Takeda Vaccines, Inc.
Most cited
By later US patents
- Multiple vaccination including serogroup C meningococcus62US 8,444,992 B2Novartis Vaccines and Diagnostics, Inc. · 2013
- Vaccine34US 6,013,264 ASmithKline Beecham Biologicals s.a. · 2000
- Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae24US 6,420,139 B12002
- Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae22US 5,723,283 AClassen Immunotherapies, Inc. · 1998
- Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae19US 5,728,385 AClassen Immunotherapies, Inc. · 1998